Neurology education. Human connection.

Answers that matter.
A community that understands.

Life with a neurological condition comes with questions. You don’t have to navigate them alone.

Education and connection for patients, caregivers and families—right here in Utah.

A healthcare professional leading a community education gathering
A place to learn. A place to belong.Local conversations. Shared understanding.
Together, we learn.
For patients.For caregivers.For the people who care.Your next conversation starts here →

Coming up next

Make room for
a better conversation.

Join us January 13 for gMG and migraine, and February 10 for multiple sclerosis (MS). Our mission welcomes the full range of neurological conditions.

Each attendee must register separately. All attendees must be 21 or older.

Rescheduled · January 13, 2027

Let’s Talk About gMG

4:00–5:30 PM · Edison House · Salt Lake City · Jeffrey Groves, MD · Ages 21+

View program details →

Learn. Ask questions. Connect. For patients, caregivers, and families age 21 or older.

More than information

You bring the questions.
We bring people together.

01 / LEARN

Make the complex feel clearer.

Approachable education from healthcare professionals, designed around real life.

02 / CONNECT

Come as you are.

Patients, caregivers and family members all have a place in the conversation.

03 / PREPARE

Leave with a next step.

Take useful questions and trusted resources back to your own healthcare team.

Reserve your seat

A seat for you.
A conversation for all of us.

This is a 21-and-older event. Select your program and enter the attendee’s contact information. Patients, caregivers, and family members are welcome, but every person attending needs their own registration.

Limited seatingWe recommend registering early. Once the room reaches capacity, registration will close.

One registration per attendee. Please submit another form for each additional person attending with you.

Why the alliance exists

Many conditions.
One shared purpose.

Wasatch Patient Alliance brings patients, caregivers, clinicians and community partners together around neurological education. gMG, migraine and MS are among the conditions we cover.

Our role is not to replace the treating clinician. It is to make reliable information easier to find, bring expert education into the community, and help people arrive at healthcare conversations better prepared.

Patient educationLive programsCurrent research updatesPartner resources

Neurology updates

A little knowledge.
A new perspective.

We curate recent reporting, guidance and research from established neurology organizations. These links are educational only and do not replace individualized medical advice.

01

Migraine

Recent guidance, research and care trends.

Updated Guideline on Migraine Prevention Medications for Adults

AHS and AAN published updated evidence-based recommendations for preventive treatment in adults with episodic and chronic migraine.

Why this matters to youPrevention is one of the most important conversations patients can have with their care team, and this is a major update to long-standing guidance.
Read source ↗

Mastering Migraine Therapies Program Returns with Updated Education

AHS refreshed its clinician education program with new content on diagnosis, treatment and emerging science in migraine care.

Why this matters to youMigraine care changes quickly. Patients benefit when clinicians have access to current, expert-vetted education.
Read source ↗

Stress, Fasting and Headache Risk in Migraine

Research examined how stress and fasting, separately and together, relate to headache onset in people with migraine.

Why this matters to youTrigger conversations can become oversimplified. This is a useful reminder that migraine patterns are often multifactorial and individual.
Read source ↗

Migraine Screening Recommended in Routine Women’s Healthcare

AHS recommended annual migraine screening for adolescent girls and women during routine healthcare visits.

Why this matters to youEarlier recognition can reduce diagnostic delays and may help more people reach appropriate care sooner.
Read source ↗
02

Multiple Sclerosis

Recent research, pipeline and community updates.

Advancing Women’s Health in Multiple Sclerosis

A discussion with MS researcher Sandra Vukusic, MD, PhD, focused on pregnancy counseling, treatment decisions and overlooked women’s health issues in MS.

Why this matters to youMS disproportionately affects women, often during reproductive years, so women’s health deserves a visible place in MS education.
Read source ↗

FDA Accepts Fenebrutinib NDA Under Priority Review for Relapsing and Primary Progressive MS

The FDA accepted a new drug application for the investigational BTK inhibitor fenebrutinib under priority review for relapsing and primary progressive MS.

Why this matters to youWe’re sharing this as a pipeline update, not a treatment recommendation. Regulatory reviews can change, but this is an important development to follow.
Read source ↗

Global Estimate of People Living with MS Reaches 3.1 Million

New Atlas of MS findings estimate about 3.1 million people worldwide are living with MS, with nearly one million in the United States.

Why this matters to youPrevalence data helps explain why access, education and support infrastructure remain so important for the MS community.
Read source ↗

Early MS Treatments Differ Most in Relapses and MRI Lesions, Not Disability

A study of 509 people newly diagnosed with MS found modest differences in relapses and MRI activity across initial treatment approaches after two years, without detected differences in disability scores.

Why this matters to youTreatment decisions are nuanced. This is a good example of why study outcomes, limitations and individual goals all matter in treatment conversations.
Read source ↗
03

Generalized Myasthenia Gravis (gMG)

Recent research, emerging approaches, and questions for your care team.

gMG Research Update: Longer-Term Treatment Data and Symptom Tracking

A September conference update describes 52-week findings for investigational gefurulimab in antibody-positive gMG, alongside research on measuring symptoms and daily function. This is a manufacturer report, not an independent treatment comparison.

Why this matters to youBetter symptom control matters most when it improves everyday life. We’re sharing this update to help patients ask how their care team measures progress and assesses new research. Conference findings and investigational treatments should not be treated as a reason to change care without your clinician.
Read source ↗

Small gMG Study Compares Plasma Filtration and Efgartigimod

A retrospective study at one hospital reviewed 31 people with gMG. Both treatment groups improved on symptom and daily-activity measures; differences in short-term changes were not statistically significant. The study was small and was not randomized.

Why this matters to youPatients may hear about several ways to reduce disease-causing antibodies. This study offers a useful starting point for asking why a particular approach fits your symptoms, health history, and care setting. It does not establish that the treatments are equivalent or that one is best for you.
Read source ↗

What’s Next in gMG? Clinical Trials to Watch

This review highlights six studies exploring new immune-targeted approaches, including cell therapies and combination strategies. It describes research directions rather than proving that these approaches are safe or effective for routine care.

Why this matters to youKnowing what is being studied can make discussions with your neuromuscular specialist more productive. We’re sharing this overview to help patients distinguish established care from experimental approaches and ask whether a clinical trial might be worth discussing. Participation has specific eligibility requirements and potential risks.
Read source ↗

Reviewed October 13, 2026. Dates reflect source publication, not the date added here. Summaries are based on publicly accessible reports and abstracts; some full articles require a subscription. Manufacturer reports and exploratory studies are labeled.

Editorial note: inclusion means we believe the topic is worth understanding—not that Wasatch Patient Alliance endorses a specific treatment, product, company or conclusion.

Trusted resources

Go deeper with established neurology organizations.

These organizations provide patient education, research updates and condition-specific resources that complement our local programming.

What to expect

Education built around real patient questions.

01

Choose a topic

Find an event or update relevant to you or someone you care for.

02

Reserve your seat

Each attendee completes a short registration with their own information.

03

Learn from an expert

Hear straightforward education from a qualified healthcare professional.

04

Leave better prepared

Take useful questions and ideas back to your personal healthcare team.

Common questions

Good to know before you attend.

Is there a cost to attend?

Our patient education events are intended to be free for registered patients and caregivers unless an event page states otherwise.

Is this medical care?

No. Events and website content provide general education and are not a substitute for diagnosis, treatment, or advice from your own healthcare professional.

Who can attend?

Patients, caregivers, and family members age 21 or older are welcome. Each attendee must register separately.

How are articles selected?

We prioritize recent, relevant content from established neurological societies, patient organizations, journals and credible clinical reporting. We also explain why we believe each item is worth sharing.

Wasatch Patient Alliance

You don’t have to have
all the answers to join us.

Follow upcoming programs and current neurology education in the Salt Lake area.

Find your next event ↗